Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

SLS

SELLAS Life Sciences Group Inc

May 15 • 02:34PM ET

1.43

Dollar change +0.06
Percentage change 4.38	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.11	Insider Own	0.69%	Shs Outstand	57.75M	Perf Week	11.72%
Market Cap	82.58M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	0.00%	Shs Float	57.36M	Perf Month	5.15%
Income	-35.81M	PEG	-	EPS next Q	-0.16	Inst Own	9.83%	Short Float	12.19%	Perf Quarter	102.03%
Sales	0.00M	P/S	-	EPS this Y	33.21%	Inst Trans	-11.61%	Short Ratio	4.53	Perf Half Y	62.50%
Book/sh	0.17	P/B	8.31	EPS next Y	15.64%	ROA	-133.77%	Short Interest	6.99M	Perf Year	-12.80%
Cash/sh	0.32	P/C	4.46	EPS next 5Y	-	ROE	-313.39%	52W Range	0.50 - 1.91	Perf YTD	34.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	61.44%	ROI	-358.20%	52W High	-25.29%	Beta	2.11
Dividend TTM	-	Quick Ratio	1.49	Sales past 5Y	22.63%	Gross Margin	-	52W Low	186.80%	ATR (14)	0.12
Dividend Ex-Date	Mar 24, 2011	Current Ratio	1.49	EPS Y/Y TTM	39.24%	Oper. Margin	0.00%	RSI (14)	57.37	Volatility	6.24% 9.66%
Employees	16	Debt/Eq	0.08	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	5.75
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	54.70%	Payout	-	Rel Volume	0.86	Prev Close	1.37
Sales Surprise	-	EPS Surprise	-31.25%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	1.54M	Price	1.43
SMA20	2.71%	SMA50	10.42%	SMA200	23.99%	Trades		Volume	1,049,639	Change	4.38%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-21	Initiated	Cantor Fitzgerald	Overweight	$18
Nov-01-18	Initiated	Oppenheimer	Outperform
Apr-02-18	Initiated	H.C. Wainwright	Buy	$11
Mar-19-18	Upgrade	Maxim Group	Hold → Buy	$13

May-14-24 10:54PM	SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-24 08:35AM	SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level (GlobeNewswire)
Apr-29-24 08:45AM	SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study (GlobeNewswire) -17.12%
Mar-28-24 10:54PM	SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023 (InvestorPlace)
04:05PM	Loading…
04:05PM	SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating Diffuse Large B Cell Lymphoma (PR Newswire)
Mar-26-24 07:35AM	SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study (GlobeNewswire)
Mar-19-24 04:05PM	SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:47AM	SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET (GlobeNewswire)
Mar-15-24 09:00AM	SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -29.03%
Mar-08-24 08:00AM	SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships (GlobeNewswire)
Mar-01-24 08:30AM	SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference (GlobeNewswire)
Feb-29-24 08:00AM	SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time (GlobeNewswire)
Feb-06-24 08:30AM	SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget (GlobeNewswire) +12.24%
08:45AM	Loading…
Jan-25-24 08:45AM	SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference (GlobeNewswire)
Jan-11-24 06:00AM	GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia (PR Newswire)
Jan-10-24 11:30AM	SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate (Zacks)
Jan-09-24 08:30AM	SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients (GlobeNewswire)
Jan-04-24 09:01AM	SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering (GlobeNewswire) -35.77%
08:41AM	Why Is Sellas Life Sciences (SLS) Stock Down 25% Today? (InvestorPlace)
Jan-03-24 08:05PM	SELLAS Life Sciences Announces Proposed Public Offering (GlobeNewswire)
07:30AM	SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones (GlobeNewswire)
Dec-27-23 08:55AM	SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma (GlobeNewswire)
Dec-21-23 08:15AM	SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas (GlobeNewswire) -5.74%
Dec-14-23 08:30AM	SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia (GlobeNewswire) +14.15%
Dec-13-23 08:30AM	SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET (GlobeNewswire)
Dec-04-23 08:47AM	SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire)
Nov-29-23 08:45AM	SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire)
Nov-13-23 08:50AM	SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS) (GlobeNewswire)
04:04PM	Loading…
Nov-09-23 04:04PM	SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:57AM	SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting (GlobeNewswire)
Oct-31-23 08:05AM	SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -16.37%
Oct-30-23 09:03AM	SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas (GlobeNewswire) +23.98%
Oct-17-23 08:45AM	SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting (GlobeNewswire) -7.87%
Oct-16-23 08:45AM	SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia (GlobeNewswire)
Oct-12-23 04:05PM	SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire) -10.42%
Oct-11-23 08:30AM	SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas (GlobeNewswire) -15.49%
Oct-10-23 04:15PM	SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia (GlobeNewswire)
07:00AM	GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL) (PR Newswire)
Sep-21-23 08:30AM	SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met (GlobeNewswire) +6.67%
Sep-18-23 04:19PM	SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) -6.83%
Aug-22-23 08:30AM	SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications (GlobeNewswire)
Aug-10-23 04:08PM	SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-15-23 09:25AM	Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely (Simply Wall St.)
Jun-28-23 04:00PM	Survival Rates Improve with SELLAS's New Treatment for Severe Lung Cancer, Phase 1 Study Shows (Benzinga)
08:30AM	SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma (GlobeNewswire)
Jun-22-23 08:45AM	SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia (GlobeNewswire)
Jun-15-23 04:05PM	SELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual Meeting (GlobeNewswire)
Jun-13-23 08:30AM	SELLAS to Participate in Maxim Group Healthcare Virtual Conference (GlobeNewswire)
May-25-23 05:05PM	SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting (GlobeNewswire)
May-16-23 08:30AM	SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia (GlobeNewswire)
May-11-23 04:12PM	SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 08:30AM	SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study (GlobeNewswire)
Apr-26-23 04:01PM	SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting (GlobeNewswire) +5.04%
Apr-20-23 08:30AM	SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia (GlobeNewswire) -5.77%
Apr-18-23 08:30AM	SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned (GlobeNewswire)
Mar-16-23 04:11PM	SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-23 08:30AM	SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal (GlobeNewswire)
Feb-24-23 08:42AM	Sellas Life Sciences raises $20 million from public offering of stock, warrants (MarketWatch) -53.66%
08:30AM	SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering (GlobeNewswire)
07:29AM	Sellas Lift Sciences stock plunges to pace premarket decliners after stock, warrants offering (MarketWatch)
Feb-23-23 04:01PM	SELLAS Life Sciences Announces Proposed Underwritten Public Offering (GlobeNewswire)
Feb-05-23 07:57AM	Here's Why We're A Bit Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Situation (Simply Wall St.)
Jan-19-23 08:30AM	SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program (GlobeNewswire)
Jan-05-23 08:30AM	SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs (GlobeNewswire)
Dec-13-22 02:49PM	SELLAS Life Sciences Highlights Data From Early Study In Blood Cancer Patients (Benzinga)
08:30AM	SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies (GlobeNewswire)
Dec-08-22 08:30AM	SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned (GlobeNewswire)
Dec-06-22 08:30AM	SELLAS Life Sciences CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute (GlobeNewswire)
Dec-01-22 08:30AM	SELLAS Life Sciences CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model (GlobeNewswire) +8.79%
Nov-30-22 08:30AM	SELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-16-22 05:28AM	SELLAS Life Sciences Group Third Quarter 2022 Earnings: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021) (Simply Wall St.) +9.38%
Nov-14-22 01:25PM	SELLAS Life Sciences Shares Tumble As Acute Myeloid Leukemia Trial Will Longer Than Anticipated (Benzinga) -43.96%
08:15AM	SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
07:50AM	SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia (GlobeNewswire)
Nov-10-22 11:09AM	SELLAS Life Sciences' GPS Combo Therapy Shows Overall Survival Of 18 Months In Pretreated Ovarian Cancer Patients (Benzinga)
08:30AM	SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer (GlobeNewswire)
Nov-03-22 09:36AM	SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +9.02%
Nov-02-22 08:30AM	SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022 (GlobeNewswire) -17.05%
Oct-25-22 09:31AM	Thinking about buying stock in Taysha Gene Therapies, Nio, Traeger, Amprius Technologies, or Sellas Life Sciences? (PR Newswire) +25.44%
Oct-17-22 08:30AM	SELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022 (GlobeNewswire)
Oct-11-22 08:30AM	SELLAS Life Sciences Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S (GlobeNewswire)
Sep-29-22 08:15AM	SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations (GlobeNewswire)
Sep-22-22 08:30AM	SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting (GlobeNewswire)
Sep-14-22 08:30AM	SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th (GlobeNewswire)
Sep-08-22 08:00AM	SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022 (GlobeNewswire)
Aug-29-22 08:24AM	The past year for SELLAS Life Sciences Group (NASDAQ:SLS) investors has not been profitable (Simply Wall St.)
Aug-24-22 10:53AM	SELLAS Life Sciences Touts Encouraging Preclinical Data For Candidate For Aggressive Form Of Prostate Cancer (Benzinga)
08:30AM	SELLAS Life Sciences Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line (GlobeNewswire)
Aug-16-22 08:30AM	SELLAS Life Sciences Announces Election of Katherine Bach Kalin to its Board of Directors (GlobeNewswire)
Aug-11-22 04:12PM	SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire) -5.62%
Aug-09-22 08:30AM	SELLAS Life Sciences GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines (GlobeNewswire)
Jul-07-22 07:30AM	SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009 (GlobeNewswire)
Jul-04-22 01:09PM	SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely (Simply Wall St.)
Jun-27-22 08:30AM	SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial (GlobeNewswire)
Jun-08-22 12:03PM	SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients (Benzinga)
08:00AM	SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo (GlobeNewswire)
Jun-02-22 08:30AM	SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th (GlobeNewswire)
May-26-22 10:10AM	Sellas' Ovarian Cancer Candidate Shows Clinical Benefit In Pretreated Patients (Benzinga) -8.81%

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLS

SELLAS Life Sciences Group Inc

Upgrade your FINVIZ experience